Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 8:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,386 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multiple Pathologies Clear all

Conditions: Kidney Diseases, Chronic Kidney Diseases
Interventions: Community health worker intervention, Standard Care (in control arm); Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Denver, Colorado • Albuquerque, New Mexico

Conditions: Benign Prostatic Hyperplasia
Interventions: Microspheres; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 40 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Atrial Fibrillation - Symptomatic
Interventions: Radiofrequency ablation; Procedure
Lead sponsor: Ohad Ziv; Other
Eligibility: 18 Years to 85 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Acute Pain
Interventions: Ketorolac Nasal Spray; Drug
Lead sponsor: Hersh, Elliot V., DMD, MS, PhD; Individual
Eligibility: 18 Years to 64 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Multiple Sclerosis, Fatigue
Interventions: OLP treatment, Usual care, Expectancy Group; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Critical Illness
Interventions: Multi-component Family Support Intervention; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,039 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 7
States / cities: Springfield, Massachusetts • New York, New York • Chapel Hill, North Carolina + 3 more

Conditions: Respiratory Failure, Respiratory Arrest, Respiratory Distress Syndrome, Acute Respiratory Failure, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure With Hypercapnia, Acute Respiratory Failure Post Surgical, Acute Respiratory Failure Postprocedural, Acute Respiratory Failure Following Trauma and Surgery, Acute Respiratory Failure Requiring Reintubation, Acute Respiratory Failure Post Traumatic, Acute Respiratory Decompensation, Shock, Shock, Septic, Shock, Cardiogenic, Acute Cardiac Failure, Multi Organ Failure, Acute Kidney Failure
Interventions: Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data; Other
Lead sponsor: Efficacy Care R&D Ltd; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Androgenetic Alopecia
Interventions: AH-001 or placebo; Drug
Lead sponsor: AnHorn Medicines Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Paroxysmal Supraventricular Tachycardia
Interventions: Etripamil NS 70 mg, Aptar Pharma Nasal Spray Bidose System; Drug · Device
Lead sponsor: Milestone Pharmaceuticals Inc.; Other
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 22
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Alamitos, California + 18 more

Conditions: Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries, Amputation
Interventions: E-TIPS; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Migraine
Interventions: Lasmiditan, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Huntsville, Alabama • Phoenix, Arizona • La Jolla, California + 10 more

Conditions: Papillary Renal Cell Carcinoma
Interventions: savolitinib, durvalumab, sunitinib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • New York, New York

Conditions: Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
Interventions: Cognitive-behavioral therapy for worry, uncertainty & insomnia; Behavioral
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP), Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions: GB001, Placebo; Drug
Lead sponsor: GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 29
States / cities: Tucson, Arizona • Jonesboro, Arkansas • Los Angeles, California + 24 more

Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Interventions: Busulfan, Fludarabine, Total-body irradiation, Cyclophosphamide, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), Bone Marrow Hematopoietic Stem Cell Transplantation, Post-transplant Cyclophosphamide, Mesna, Tacrolimus, Mycophenolate Mofetil, Patient-Reported Outcomes; Drug · Radiation · Procedure + 1 more
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: 1 Year and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 39
States / cities: Duarte, California • San Francisco, California • Stanford, California + 28 more

Conditions: Prader-Willi Syndrome, Aggression, Self-Injurious Behavior, Pathologic Processes, Behavioral Symptoms, Intellectual Disability, Neurobehavioral Manifestations, Neurologic Manifestations, Nervous System Diseases, Abnormalities, Multiple, Congenital Abnormalities, Chromosome Disorders, Genetic Diseases, Inborn, Obesity, Overnutrition, Nutrition Disorders, Antihypertensive Agents, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action, Physiological Effects of Drugs, Skin-Picking
Interventions: Guanfacine Extended Release, Placebo; Drug · Other
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 6 Years to 35 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Myelodysplasia, Lymphoma, Non-Hodgkin's, Mantle-Cell Lymphoma, Hodgkin's Disease, Multiple Myeloma, Myelofibrosis
Interventions: Cyclophosphamide, Fludarabine, Cyclosporine, Mycophenolate mofetil, Basiliximab; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Down Syndrome, Fetal Aneuploidy
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2028
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 6 more

Conditions: Atrial Fibrillation
Interventions: Ablation; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: South Bend, Indiana • Boston, Massachusetts

Conditions: Health Adult Subjects, Obesity & Overweight
Interventions: TIX100, Placebo; Drug
Lead sponsor: TIXiMED, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Glioma, Glioblastoma, Brain Tumor, Recurrent
Interventions: ANG1005, Bevacizumab; Drug
Lead sponsor: Angiochem Inc; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 12
States / cities: La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 6 more

Conditions: Anaemia
Interventions: GSK1278863, Placebo, rhEPO; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 17
States / cities: Azusa, California • Los Angeles, California • San Dimas, California + 13 more

Conditions: Sjögren Syndrome
Interventions: CFZ533, Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 8
States / cities: Suwanee, Georgia • Indianapolis, Indiana • Baton Rouge, Louisiana + 5 more

Conditions: Osteoarthritis of the Knee, Pain
Interventions: REGN5069, Matching Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: DeLand, Florida • Jupiter, Florida • Miami, Florida + 1 more

Search by objective public record fields.

NAVIGATE Kidney: A Multi-level Intervention to Reduce Kidney Health Disparities

Efficacy of Prostatic Artery Embolization (PAE) in Patients With Severe Benign Prostatic Hyperplasia (BPH)

Low Voltage-Directed Catheter Ablation for Atrial Fibrillation

Intranasal Ketorolac for Postsurgical Pain in Dental Implant Patients

Open-Label Placebos to Treat Fatigue in Multiple Sclerosis

Multi-component Family Support Tool Intervention (FST)

Postoperative Respiratory Abnormalities

Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration

Safety Study of Intranasal Etripamil for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia (PSVT). NODE-302

Telehealth Pain Self-Management for Employed Adults

A Study of Lasmiditan (LY573144) Over Four Migraine Attacks

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors

GB001 in Adult Participants With Chronic Rhinosinusitis

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

In-Vivo Activated T-Cell Depletion to Prevent GVHD

Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy

Low Fluoroscopy Afib Ablation Registry

A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

ANG1005 in Patients With Recurrent High-Grade Glioma

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjogren's Syndrome

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee